Logo

AN2 Therapeutics, Inc.

ANTX

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.ā€ā€ā€Ž ā€Ž

Healthcare

Biotechnology

1 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.28

Price

+0.79%

$0.01

Market Cap

$34.977m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$37.380m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$1.24

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$68.842m

$75.825m

Assets

$6.983m

Liabilities

-

Debt
Debt to Assets

0.00%

-

Debt to EBITDA
Free Cash Flow

-$35.503m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases